Cubit Diagnostics today announced it has closed its latest round of SAFE (Simple Agreement for Future Equity) financing. The proceeds will fund the company's next phase of work, centered on locking in ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Cloud-Clone has built an integrated antibody R&D and manufacturing platform, focusing on enhancing product consistency and MP for research and diagnostics. HUSTON, TX, UNITED STAT ...

Miniaturization has become a key strategy in modern assay development — reducing reagent consumption, increasing throughput, ...

A new Armatus publication summarizes a novel potency assay platform to advance gene silencing therapies for rare neuromuscular diseases.

Chantle Edillor used a fascination with sourdough starters to pivot from studying human diseases to exploring yeast-based ...

New service offering enables GR/NF-κB transrepression studies to support deeper mechanism-of-action insight in drug ...

When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...

The oral presentation, titled, “¹⁸⁶Rhenium-Nanoliposomes (¹⁸⁶RNL) for the Treatment of Leptomeningeal Metastases: Translational Insights from Clinical and Preclinical Models,” was delivered by ...

Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...

CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today a new payer coverage agreement with Blue Shield of California, ...

The growing complexity of the field reinforces the need for standards ensuring product quality, consistency, and patient ...